Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth but faces market and regulatory hurdles in Q3 2024.

Nov. 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals ... opinion from the Committee for Medicinal Products for Human Use (CHMP) in September 2024. Expect regulatory decisions in the U.K ...

Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...

Unfortunately for investors, it missed on both the top and bottom lines. Apellis unveiled those results before market hours on Tuesday, disclosing that its revenue for the quarter was just under ...

Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...

Overall, Apellis reported total third-quarter revenues of $196.8 million, up 78% year over year. Beyond Syfovre, the company’s paroxysmal nocturnal hemoglobinuria drug Empaveli grew sales 0.4% ...

Apellis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:APLS) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a... On January 16 ...

We were disappointed with the negative CHMP opinion despite multiple analyses ... paradigm for patients with C3G and IC-MPGN. At Apellis, we have spent the last two decades investigating C3 ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...